Association of antiretroviral resistance genotypes with response to therapy - Comparison of three models

Antiviral Therapy

Volumn 7, Issue 3, 2002, Pages 151-157

  Quigg, Marlynne ^a   Frost, Simon D W ^a   McDonagh, Susan ^b   Burns, Sheila M ^b   Clutterbuck, Daniel ^c   McMillan, Alexander ^c   Leen, Clifford S ^d   Leigh Brown, Andrew J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b CITY HOSPITAL   (United Kingdom)

^c ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^d WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AMINO ACID SEQUENCE; FEMALE; GENE MUTATION; GENETIC RESISTANCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; PRIORITY JOURNAL; REVIEW; TECHNIQUE; TREATMENT OUTCOME;

ADULT; AMINO ACID SEQUENCE; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV; HIV INFECTIONS; HIV PROTEASE; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MUTATION; PHYLOGENY; RETROSPECTIVE STUDIES; VARIATION (GENETICS);

EID: 0036768683     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. Hirsch MS, Brun-Vezinet F, D'Aquila RT, Hammer SM, Johnson VA, Kuritzkes DR, Loveday C, Mellors JW, Clotet B, Conway B, Conway B, Demeter LM, Vella S, Jacobsen DM & Richmann DD. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. Journal of the American Medicial Association 2000; 283:2417-2426.
2. Lorenzi P, Opravil M, Hirschel B, Chave JP, Furrer HJ, Sax H, Perneger TV, Perrin L, Kaiser L & Yerly S. Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study. AIDS 1999; 13:F17-F21.
3. Precious HM, Günthard HF, Wong JK, D'Aquila RT, Johnson VA, Kuritzkes DR, Richman DD & Leigh Brown AJ. Multiple regression analysis of sequence variants in HIV-1 reverse transcriptase at onset of antiretroviral therapy can predict long term virological response. AIDS 2000; 14:31-36.
4. DeGruttola V, Dix L, D'Aquila R, Holder D, Phillips A, Ait-Khaled M, Baxter J, Clevenbergh P, Hammer S, Harrigan R, Katzenstein D, Lanier R, Miller M, Para M, Yerly S, Zolopa A, Murray J, Patick A, Miller V, Castillo S, Pedneault L & Mellors J. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antiviral Therapy 2000; 5:41-48.
5. Zolopa AR, Shafer RW, Warford A, Montoya JG, Hsu P, Katzenstein D, Merigan TC & Efron B. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Annals of Internal Medicine 1999; 131:813-821.
6. Hertogs K, Bloor S, De V, van Den Eynde C, Dehertogh P, van Cauwenberge A, Sturmer M, Alcorn T, Wegner S, van Houtte M, Miller V & Larder BA. A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V. Antimicrobial Agents and Chemotherapy 2000; 44:568-573.
7. Smith SW, Overbeek R, Woese CR, Gilbert W & Gillevet PM. The genetic data environment and expandable GUI for multiple sequence analysis. Computational Applied Bioscience 1994; 10:671-675.
8. Korber BT, Learn G, Mullins JI, Hahn BH & Wolinsky S. Protecting HIV databases. Nature 1995; 378:242-244.
9. Schinazi RF, Larder BA & Mellors JW. Mutations in retroviral genes associated with drug resistance. International Antiviral News 1996; 4:95-107.
10. Breiman L, Friedman JH, Olshen RA & Stone CJ. Classification and Regression Trees. 1984; pp. 1-358. Belmont, Calif.: Wadsworth International.
11. Harrigan PR, Hertogs K, Verbiest W, Pauwels R, Larder B, Kemp S, Bloor S, Yip B, Hogg R, Alexander C & Montaner JS. Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting. AIDS 1999; 13:1863-1871.
12. Hertogs K, Bloor S, De Vroey V, van den Eynde C, Dehertogh P, van Cauwenberge A, Sturmer M, Alcorn T, Wegner S, van Houtte M, Miller V & Larder BA. A Novel Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutational Pattern Confers Phenotypic Lamivudine Resistance in the Absence of Mutation 184V. Antimicrobial Agents & Chemotherapy 2000; 44:568-573.
13. Sevin AD, DeGruttola V, Nijhuis M, Schapiro JM, Foulkes AS, Para MF & Boucher CA. Methods for investigation of the relationship between drug-susceptibility phenotype and human immunodeficiency virus type 1 genotype with applications to AIDS clinical trials group 333. Journal of Infectious Diseases 2000; 182:59-67.
14. Leigh Brown AJ, Precious HM, Whitcomb JM, Wong JK, Quigg M, Huang W, Daar E, D'Aquila RT, Keiser PH, Connick E, Hellmann NS, Petropoulos CJ, Richman DD & Little SJ. Reduced susceptibility of HIV-1 from patients with primary HIV infection to non-nucleoside reverse transcriptase inhibitors is associated with variation at novel amino acid sites. Journal of Virology 2000; 74:10269-10273.